Altogether, we propose that NANOG+ immune-refractory tumor cells enriched by immune selection drive the immune-refractory feature of the TME by simultaneously disrupting multiple steps of the antitumor immunity cycle, which provokes resistance to PD-1 blockade (Figure 8, A and B). The gene discussed is PDCD1; the disease is neoplasm.